Cited by 830Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Sequist, Lecia V., Martins, Renato G., Spigel, David, Grunberg, Steven M., Spira, Alexander, Jänne, Pasi A., Joshi, Victoria A., McCollum, David, Evans, Tracey L., Muzikansky, Alona, Kuhlmann, Georgiana L., Han, Moon, Goldberg, Jonathan S., Settleman, Jeffrey, Iafrate, A. John, Engelman, Jeffrey A., Haber, Daniel A., Johnson, Bruce E., Lynch, Thomas J.·2008·Journal of Clinical Oncology

DOI 10.1200/jco.2007.14.8494

Open this paper in CoChat — free account

Abstract

PURPOSE: Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response in patients with non-small-cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). The multicenter iTARGET trial prospectively examined first-line gefitinib in advanced NSCLC patients harboring EGFR mutations and explored the significance of EGFR mutation subtypes and TKI resistance mechanisms. PATIENTS AND METHODS: Chemotherapy-naïve patients with advanced NSCLC with >or= 1 clinical characteristic associated with EGFR mutations underwent direct DNA sequencing of tumor tissue EGFR exons 18 to 21. Patients found to harbor any EGFR mutation were treated with gefitinib 250 mg/d until progression or unacceptable toxicity. The primary outcome was response rate. RESULTS: Ninety-eight patients underwent EGFR screening and mutations were detected in 34 (35%). EGFR mutations were primarily exon 19 deletions (53%) and L858R (26%) though 21% of mutation-positive cases had less common subtypes including exon 20 insertions, T790M/L858R, G719A, and L861Q. Thirty-one patients received gefitinib. The response rate was 55% (95% CI, 33 to 70) and median progression-free survival was 9.2 months (95% CI, 6.2 to 11.8). Therapy was well tolerated; 13% of patients had grade 3 toxicities including one grade 3 pneumonitis. Two patients with classic activating mutations exhibited de novo gefitinib resistance and had concurrent genetic anomalies usually associated with acquired TKI resistance, specifically the T790M EGFR mutation and MET amplification. CONCLUSION: First-line therapy with gefitinib administered in a genotype-directed fashion to patients with advanced NSCLC harboring EGFR mutations results in very favorable clinical outcomes with good tolerance. This strategy should be compared with combination chemotherapy, the current standard of care.

Integrity signals

Registry

Crossref · 10.1200/jco.2007.14.8494

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Self-citation
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citation

Flagged first, then by citations

Show all 46 references

Sorted by citations

Items 701–800 of 830

Efficacy of gefitinib as a first-line single agent treatment in patients with advanced non-small cell lung cancer
Yin, Y., Geng, Y., Li, X., Hu, X., Chen, X., Li, W., & Shu, Y. (2009) · 南京医科大学学报：英文版 · doi:10.1016/s1007-4376(09)60088-5 · Cited by 2
Evolution and clinical impact of genetic epistasis within EGFR-mutant lung cancersPreprint
Blakely, C. M., Watkins, T. B. K., Wu, W., Gini, B., Chabon, J. J., McCoach, C. E., McGranahan, N., Wilson, G. A., Birkbak, N. J., Olivas, V. R., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/117291 · Cited by 2
Minimal residual disease after radical surgery in EGFR-mutant non-small cell lung cancer
Masago, K., Horio, Y., Fujita, S., & Yatabe, Y. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.09.09 · Cited by 2
Auto-adaptive Alpha Allocation: A Strategy to Mitigate Risk on Study Assumptions
Shentu, Y., Chen, C., Pang, L., & Beckman, R. A. (2017) · Statistics in Biosciences · doi:10.1007/s12561-017-9192-1 · Cited by 1
Gefitinib
Tridente, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809400-6.00006-8 · Cited by 1
Capturing two new salts of the anticancer drug gefitinib
Zhai, L., Zhu, Z., Guo, L., Yu, J., Dong, H., & Zhang, G. (2022) · Molecular Crystals and Liquid Crystals · doi:10.1080/15421406.2021.1912689 · Cited by 1
An allele-specific quantitative PCR strategy for detection of EGFR T790M mutations by liquid biopsy in non-small cell lung cancer patients
Baburaj, G., Parida, P., Udupa, K., Pai, A., Damerla, R. R., & Rao, M. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144447 · Cited by 1
EGFR Exon 20 Insertion–Mutated Non-Small Cell Lung Cancer: Current Treatment Landscape and Future Directions
Lau, L. Y., Sahib, N. R. B. M., Cangco, C. Y. P., & Tan, A. C. (2026) · Drugs · doi:10.1007/s40265-026-02329-7 · Cited by 1
Detection of EGFR T790M Mutation in Pericardial Effusion from a Non-Small Cell Lung Cancer Patient with Erlotinib Therapy
Sakai, A., Kasahara, K., & Sone, T. (2013) · Case Reports in Oncology · doi:10.1159/000345947 · Cited by 1
A Patient with Advanced Lung Adenocarcinoma Effectively Treated with Gemcitabine Plus Vinorelbine After Failure with Gefitinib
Hashimoto, H., Nakagishi, Y., Obara, K., & Oshika, Y. (2010) · Haigan · doi:10.2482/haigan.50.297 · Cited by 1
Ethnic variation in response to EGFR inhibitors
Loong, H. H.-F., Wei, J., & Mok, T. S. K. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.04.003 · Cited by 1
Les traitements biologiques du cancer bronchique en 2008… et dans un futur proche
Bergot, E., Levallet, G., & Zalcman, G. (2008) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(08)82017-7 · Cited by 1
Personalized Medicine: Development of a Predictive Computational Model for Personalized Therapeutic Interventions
Kureshi, N. (2013) · DalSpace (Dalhousie University) · Cited by 1
Behavior of circulating epithelial tumor cells (CETC) and FISH (fluorescence in situ hybridisation) of epidermal growth factor receptor (EGFR)-gene amplification in lung cancer patients during the course of therapy
Sherif, M. E., Schneider, C., Rabenstein, C., Hassab, A. H., Bordiny, M. M. E., Ayad, M. W., & Pachmann, K. (2013) · Advances in Lung Cancer · doi:10.4236/alc.2013.21001 · Cited by 1
Molecular Targeted Therapy in Lung Cancer
Ahn, M. (2014) · Hanyang Medical Reviews · doi:10.7599/hmr.2014.34.1.37 · Cited by 1
Overcoming Resistance to EGF Receptor Tyrosine Kinase Inhibitors in EGFR -mutated NSCLC
Saad, S., Huang, K., & Halmos, B. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.35 · Cited by 1
Targeted Therapies for Non-small-Cell Lung Cancer
Metro, G., & Crinò, L. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-615-9_4 · Cited by 1
Current and Emerging Roles of Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small Cell Lung Cancer
Mountzios, G., Owonikoko, T. K., Karamouzis, M. V., & Argiris, A. E. (2010) · The Open Lung Cancer Journal · Cited by 1
ROS-1 rearrangements in non-small cell lung cancer (NSCLC): a new target for a small subset of patients but a giant leap in therapeutics
Brosseau, S., Oulkhouir, Y., Naltet, C., Magnier, R., Lechapt, E., & Zalcman, G. (2016) · Current Pulmonology Reports · doi:10.1007/s13665-016-0138-8 · Cited by 1
How Should Targeting Agents Be Used?
Satouchi, M. (2012) · Haigan · doi:10.2482/haigan.52.142 · Cited by 1
Tratamiento con afatinib en primera línea EGFR M+. Resultados según subtipo de mutación
Juan, Ó. (2016) · Medicina Clínica · doi:10.1016/s0025-7753(16)30258-5 · Cited by 1
Adenocarcinoma of the lung
Flieder, D. B., Borczuk, A., & Noguchi, M. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139018760.030 · Cited by 1
Evaluating a Novel Summary Visualization for Clinical Trial Reports: A Usability Study.
Tong, M., Hsu, W. W. Y., & Taira, R. K. (2016) · PubMed Central · Cited by 1
Somatic Diseases (Cancer)
Sehn, J. K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404748-8.00020-4 · Cited by 1
Design, Synthesis, and Anticancer Activity of Substituted Styryl Incorporated Quinazoline Derivatives
Kala, P., & Ramachandran, D. (2020) · Russian Journal of General Chemistry · doi:10.1134/s1070363220100187 · Cited by 1
A multiparametric fluorescent visualization approach for detecting drug resistance in living cancer cells
Zhou, Z., Wang, Y., Shao, Z., Zhang, G., Jiang, H., Tang, Y., Huang, Z., Zhu, Y., & Li, J. (2023) · Talanta · doi:10.1016/j.talanta.2023.124564 · Cited by 1
Tumor Inflammatory Microenvironment in Lung Cancer: Heterogeneity and Implications
Bhatia, A., Sobti, R. C., & Sharma, S. (2023) · Springer eBooks · doi:10.1007/978-981-99-2196-6_20-1 · Cited by 1
Somatic Genetic Alterations and Implications for Targeted Therapies in Cancer (GIST, CML, Lung Cancer)
Shaw, A. T., Attar, E. C., Choy, E., & Engelman, J. A. (2010) · Springer eBooks · doi:10.1007/978-0-387-93846-2_15 · Cited by 1
Self-citation
[Gefitinib in Advanced Non-small-cell Lung Cancer.].
Zhu, L.-N., Yang, Z., & Wang, S. (2009) · PubMed · doi:10.3779/j.issn.1009-3419.2009.05.011 · Cited by 1
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
Takeda, M., Okamoto, I., & Nakagawa, K. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv471.20 · Cited by 1
Radiation Recall Pneumonitis Induced by Gefitinib in a Patient with Lung Adenocarcinoma and EGFR Mutation
Inomata, M., Miya, T., & Kokubo, Y. (2010) · Haigan · doi:10.2482/haigan.50.937 · Cited by 1
Incorporating Pharmacogenomics in Drug Development
Yin, O. Q. P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-391918-2.00018-4 · Cited by 1
Design, Synthesis and Antitumor Activity of Quinazoline Derivatives Bearing 2,3-Dihydro-indole or 1,2,3,4-Tetrahydroquinoline
OuYang, Y., Zhao, B., Chen, X., Wang, C., Zhang, H., Jia, S., Zhu, W., & Zheng, P. (2018) · Letters in Drug Design & Discovery · doi:10.2174/1570180815666180801121220 · Cited by 1
[Advanced Research on Non-small Cell Lung Cancer with De Novo T790M Mutation].
Wang, X., & Zhong, D. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.05.10 · Cited by 1
A novel virtual barcode strategy for accurate panel-wide variant calling in circulating tumor DNA
Wu, L., Deng, Q., Xu, Z., Zhou, S., Li, C., & Li, Y. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-3412-2 · Cited by 1
Adenocarcinoma de pulmón con doble mutación de EGFR: L858R y G719X
Castellanos, P. C., Sainz, L. G., Esteban, M. I., & de Castro, J. (2020) · Revista Española de Patología · doi:10.1016/j.patol.2019.11.003 · Cited by 1
A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations
Song, S.-Y., Ha, S., Park, J., Park, S. J., Shin, S. H., Oak, C., Choi, J. Y., Yoon, S. W., Kim, J.-A., Yoon, S. H., et al. (2020) · Medicine · doi:10.1097/md.0000000000023455 · Cited by 1
Mechanisms of Resistance to Epidermal Growth Factor Receptor (EGFR) in Non‐Small Cell Lung Cancer
Massarelli, E. (2014) · Lung Cancer · doi:10.1002/9781118468791.ch27 · Cited by 1
A systems pathology model for predicting overall survival in patients with refractory, advanced non-small cell lung cancer (NSCLC) treated with gefitinib
Donovan, M. J., Kotsianti, A., Bayer‐Zubek, V., Verbel, D., Clayton, M., Hamann, S., Capodieci, P., Pang, H.-Y., Cardó, C. C., Parums, D. V., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.18065 · Cited by 1
Case 23-2008
Sequist, L. V. D., Settleman, J. E., Ackman, J. B., & Iafrate, A. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmcpc0803971 · Cited by 1
Self-citation
Treatment of subtypes in non-small cell lung cancer
de Waal, L. M. (2012) · Utrecht University Repository (Utrecht University) · Cited by 1
Principles of Medical Oncology and Chemotherapy
Murphy, J. E., & Ryan, D. P. (2011) · Springer eBooks · doi:10.1007/978-1-4419-1469-9_1
Management of advanced non-small cell lung cancer: moving towards a more personalised approach
Lind, J. S. W. (2012) · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)
Modulation of DNA strand break induction and repair bytyrosine kinase inhibitors targeted against EGFR and HER2
Bhosle, J. (2012) · UCL Discovery (University College London)
EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Clinical Trial Review
Mileham, K. F., Kim, E. S., & William, W. N. (2014) · Lung Cancer · doi:10.1002/9781118468791.ch26
Predictive and Prognostic Implications of EGFR Mutations
Cappuzzo, F. (2014) · Springer eBooks · doi:10.1007/978-3-319-03059-3_4
Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib
Naito, Y., & Goto, K. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2122
Drugs, Genomic Response Signatures, and Customized Cancer Therapy
Rosell, R., Morán, T., & Tarón, M. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139021500.028
[Analyzing the Sensitivity of EGFR-L861Q Mutation to TKIs and A Case Report].
Wang, X., Dong, Y., Liang, T., Zhang, X., Ma, K., & Cui, Y. (2015) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2015.09.11
Developments in the Management of Advanced Non Small Cell Lung Cancer
Kopitopoulou, A., Ntanos, I., Saif, M. W., & Syrigos, K. (2013) · Journal of Cancer Therapy · doi:10.4236/jct.2013.41027
Targeted Therapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer—Patient Selection Changes the Fate of Gefitinib
Locke, S. R. A. I. (2010) · Clinical Medicine Reviews in Oncology · doi:10.4137/cmro.s3276
Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer
Wilson, C. (2010) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s9974
Targeted Therapy For Lung Cancer: Reviewing the Cost and Its Effect on Treatment Decisions
Lim, C. H., Sergi, M., & Leighl, N. B. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.36
Fibroblast growth factor receptors (FGFR) as possible therapeutic targets in human non-small cell lung cancer
Grusch, M., & Berger, W. (2010) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-010-0182-y
Weekly low-dose Semustine in a patient with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) coupled with subcutaneous involvement and positive O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation
Ren, W., Xie, L., Yan, J., Kong, W., Yang, Y., Zhu, L., Hu, W., Xu, X., Qian, X., & Liu, B. (2012) · The Chinese-German Journal of Clinical Oncology · doi:10.1007/s10330-012-1031-8
Les outils biologiques en pratique : aide au diagnostic, au pronostic et au traitement du cancer bronchique
Mazières, J., Rouquette, I., & Brouchet, L. (2009) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(09)72497-8
Efficacy and Safety of Gefitinib or Platinum plus Taxane in Egfr-Mutant Advanced Non-Small Cell Lung Cancers: A Meta-Analysis of First-Line Randomized Controlled Trials
Aydıner, A. (2012) · Journal of Cancer Therapy · doi:10.4236/jct.2012.324060
Gefitinib First or Gefitinib Second
Janne, P. A. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200806-910ed
Self-citation
Approaching Resistance to Targeted Inhibition of PI3K in Breast Cancer
Ilić, N. (2011) · doi:10.21236/ada555900
The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example
Li‐Wan‐Po, A., Farndon, P. A., Kobayashi, S. S., Mitsudomi, T., & Potter, V. A. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p496
Gefitinib: Re-Emerging from the Shadows
Martin, P., Owen, S. P., & Leighl, N. B. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.42
Overview of Efficacy and Limitation of Standard and Targeted Therapy for Malignant Disease Using Lung Cancer as a Case Study
Nguyen, D. M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0020-3_1
Quantitative Analysis of ( 11 C)-Erlotinib PET Demonstrates Specific Binding for Activating Mutations of the EGFR
Petrulli, J. R., Sullivan, J. M., Zheng, M., Bennett, D. C., Charest, J., Huang, Y. H., Morris, E. D., & Contessa, J. N. (2013)
Clinical Trials and Translational Applications in Cancer Therapy
Khabele, D., & Beech, D. J. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0131-6_21
Targeted Therapy in Solid Tumors: Lung Cancer
Waqar, S. N., Morgensztern, D., & Herbst, R. S. (2015) · doi:10.1002/9781118468678.ch23
Research Progress of Molecular Target Therapy in Non-Small Cell Lung Cancer
张, 琨. (2016) · Advances in Clinical Medicine · doi:10.12677/acm.2016.61004
Contrôle de la signalisation oncogénique du mutant L858R de l'EGFR par la protéine
Ozenne, P. (2011)
Brain metastasis from non-small cell lung cancer: sustained response with erlotinib
Velagapudi, V. M., & Piperdi, B. (2009) · Community Oncology · doi:10.1016/s1548-5315(11)70544-7
Testing for EGFR mutations: an emerging strategy for selecting treatment for adenocarcinoma of the lungs
Sequist, L. V. D. (2009) · Community Oncology · doi:10.1016/s1548-5315(11)70545-9
Self-citation
Signal Transduction Inhibitors of the HER Family
Brzezniak, C. E., Carter, C. A., Thomas, A., & Giaccone, G. (2013) · CRC Press eBooks · doi:10.1201/b15944-3
First-line therapy of advanced non-small cell lung cancer with activatingEGFRmutations
Zhou, C. (2012) · Informa Healthcare eBooks · doi:10.3109/9781841848679.007
Highlights From: The 13th World Conference on Lung Cancer San Francisco, CA July 31–August 4, 2009
(2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.043
Targeting Oncoproteins for Molecular Cancer Therapy
Allen, J. E., & El‐Deiry, W. S. (2016) · Springer eBooks · doi:10.1007/978-1-59745-458-2_38
Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer
Mirone, G., Perna, S., & Marfè, G. (2016) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-46091-8_2
A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting
Gridelli, C., & Losanno, T. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.11.91
Future Perspectives for Rheumatoid Arthritis and Other Autoimmune Diseases
Sokolove, J. B. (2016) · ASM Press eBooks · doi:10.1128/9781555818722.ch96
Progress toward resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitor
Zhang, L., Zhang, X., & Zhao, L. (2016) · Open Life Sciences · doi:10.1515/biol-2016-0056
Place des thérapeutiques biologiques ciblées
Wislez, M., & Cadranel, J. L. (2008) · ONCOLOGIE · doi:10.1007/s10269-008-0919-y
A Meta-analytic Approach for Testing Evolutionary Hypotheses of Acquired Resistance in Metastatic Cancer
Bhardwaj, K. (2014) · uO Research (University of Ottawa) · doi:10.20381/ruor-3562
Prise en charge des métastases cérébrales des cancers bronchiques non à petites cellules
Noach, P., Descourt, R., & Quéré, G. (2018) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(18)30036-3
Frontline Systemic Therapy Options in Nonsmall Cell Lung Cancer
Ramalingam, S. S., Pillai, R. N., Reinmuth, N., & Reck, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00044-5
Implementing Companion Diagnostic Testing in the Clinic
Schildgen, V., & Schildgen, O. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813539-6.00022-5
MET Receptor Amplification Drives Resistance to Anti-EGFR Therapies
Romano, P. M., Castañón, E., Hollebecque, A., Lacroix, L., Auger, N., Angevin, E., Tselikas, L., Ammari, S., Soria, J., & Massard, C. (2019) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_7_19
Author response: Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
Haven, B., Heilig, E., Donham, C., Settles, M., Vasilevsky, N., Owen, K. A., & Reproducibility Project: Cancer Biology (2015) · eLife · doi:10.7554/elife.09462.003
Identifying and Analyzing Indel Variants in the Human Genome Using Computational Approaches
Hasan, M. S. (2019) · VTechWorks (Virginia Tech)
Survival of gefitinib treated advanced non-small cell lung cancer patients harbouring EGFR mutations
Bangash, N. S. A., Ismail, N. E., & Hashim, N. (2021) · Pharmacy & Pharmacology International Journal · doi:10.15406/ppij.2021.09.00342
Quantitative Imaging in Lung Cancer
Zhao, B., & Dercle, L. (2021) · doi:10.1063/9780735423558_008
EGFR-Targeted Therapies in Non-small Cell Lung Cancer
Cappuzzo, F. (2014) · Springer eBooks · doi:10.1007/978-3-319-03059-3_5
Oncologie thoracique
Cortot, A. B., Dansin, É., & Scherpereel, A. (2011) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(11)70056-8
Research Highlights
Lim, W., Huat, T. B., Kanesvaran, R., & Chowbay, B. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.10.1381
Lung Cancer
Zimmermann, S., Fontecedro, A. C., Stahel, R. A., & Peters, S. (2012) · Springer eBooks · doi:10.1007/978-0-85729-787-7_3
The development and implementation of EGFR inhibitors in advanced NSCLC
Neuwelt, A. J., & Camidge, D. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822833-3.00007-3
Akciğer Kanserinde Güncel Genetik Algoritma ve Tedavi Seçenekleri
Arslan, S. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub80.c247
Is EGFR gene mutation testing necessary in smokers with non-small cell lung cancer?
Zhu, J., Yuan, J., Dou, Y., Tian, W., Li, S., Wang, H., & Li, Z. (2017) · Oncology and Translational Medicine · doi:10.1007/s10330-017-0228-8
Additional file 12 of A novel virtual barcode strategy for accurate panel-wide variant calling in circulating tumor DNA
Wu, L., Deng, Q., Xu, Z., Zhou, S., Li, C., & Li, Y. (2020) · Figshare · doi:10.6084/m9.figshare.12082251
Additional file 14 of A novel virtual barcode strategy for accurate panel-wide variant calling in circulating tumor DNA
Wu, L., Deng, Q., Xu, Z., Zhou, S., Li, C., & Li, Y. (2020) · Figshare · doi:10.6084/m9.figshare.12082257
Additional file 11 of A novel virtual barcode strategy for accurate panel-wide variant calling in circulating tumor DNA
Wu, L., Deng, Q., Xu, Z., Zhou, S., Li, C., & Li, Y. (2020) · Figshare · doi:10.6084/m9.figshare.12082248
Additional file 10 of A novel virtual barcode strategy for accurate panel-wide variant calling in circulating tumor DNA
Wu, L., Deng, Q., Xu, Z., Zhou, S., Li, C., & Li, Y. (2020) · Figshare · doi:10.6084/m9.figshare.12082242
Additional file 13 of A novel virtual barcode strategy for accurate panel-wide variant calling in circulating tumor DNA
Wu, L., Deng, Q., Xu, Z., Zhou, S., Li, C., & Li, Y. (2020) · Figshare · doi:10.6084/m9.figshare.12082254
Additional file 15 of A novel virtual barcode strategy for accurate panel-wide variant calling in circulating tumor DNA
Wu, L., Deng, Q., Xu, Z., Zhou, S., Li, C., & Li, Y. (2020) · Figshare · doi:10.6084/m9.figshare.12082260

Authors: Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., Kuhlmann, G. L., Han, M., Goldberg, J. S., Settleman, J., Iafrate, A. J., Engelman, J. A., Haber, D. A., Johnson, B. E., & Lynch, T. J.
Affiliations: Brigham and Women's Hospital (US)
From the Massachusetts General Hospital Cancer Center; Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital; Department of Pathology, Massachusetts General Hospital; Department of Biostatistics, Massachusetts General Hospital, Boston; Harvard Medical School/Partners Health Care Center for Genetics and Genomics, Cambridge, MA; University of Washington, Seattle, WA; Sarah Cannon Research Institute, Nashville, TN; Fletcher Allen Health Care, Burlington, VT; Fairfax-Northern...
ORCID: Sequist, Lecia V.
Martins, Renato G.
Spigel, David
Spira, Alexander
Evans, Tracey L.
Muzikansky, Alona
Han, Moon
Settleman, Jeffrey
Iafrate, A. John
Engelman, Jeffrey A.
Haber, Daniel A.
Johnson, Bruce E.
Lynch, Thomas J.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2008-05-20
Volume: 26
Issue: 15
Pages: 2442-2449
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2007.14.8494
OpenAlex: W2101329867
Cited by: 820
References: 46
Citations by year: 2026: 4 · 2025: 14 · 2024: 9 · 2023: 11 · 2022: 20 · 2021: 22 · 2020: 34 · 2019: 29 · 2018: 51 · 2017: 51 · 2016: 54 · 2015: 57 · 2014: 68 · 2013: 69 · 2012: 60
FWCI: 81.10
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: gefitinib, non-small cell lung cancer, EGFR mutation, first-line therapy, EGFR tyrosine kinase inhibitors, exon 19 deletion, L858R mutation, T790M mutation, MET amplification, progression-free survival, response rate, pneumonitis, genotype-directed therapy
MeSH terms: Gefitinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Prospective Studies, Quinazolines, Survival Rate, Central Nervous System Neoplasms, Treatment Outcome, In Situ Hybridization, Fluorescence, Carcinoma, Large Cell, Disease-Free Survival, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks